Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare ConferenceBusiness Wire · Oct 15, 2026
Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facilityProactive Investors · Oct 7, 2026
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor WebinarBusiness Wire · Oct 7, 2026
Rocket Pharmaceuticals (NASDAQ:RCKT) Given “Buy” Rating at Chardan CapitalDefense World · Oct 7, 2026
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety ResetDefense World · Oct 7, 2026
Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data TranscriptSeeking Alpha · Oct 7, 2026Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | $0.86 | $1.08 | Beat |
| May 7, 2026 | -$0.41 | -$0.42 | Miss |
| Feb 26, 2026 | -$0.42 | -$0.38 | Beat |
| Nov 6, 2025 | -$0.48 | -$0.45 | Beat |
| Aug 7, 2025 | -$0.57 | -$0.59 | Miss |
| May 8, 2025 | -$0.59 | -$0.56 | Beat |